medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-21-142-146medsovet-5486Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYПрименение алендроната в терапии остеопорозаUse of alendronate in the therapy of osteoporosishttps://orcid.org/0000-0001-7167-2187ЕршоваО. Б.ErshovaO. B.

Ершова Ольга Борисовна, д.м.н., профессор кафедры терапии Института последипломного образования

150000, Россия, Ярославль, ул. Революционная, д. 5

Olga B. Ershova, Dr. of Sci. (Med.), Professor of Chair for Therapy, Institute of Postgraduate Education

5, Revolutsionnaya St., Yaroslavl, 150000, Russia

yarosteoporosis@list.ruЯрославский государственный медицинский университетРоссияYaroslavl State Medical UniversityRussian Federation201926012020021142146Copyright © Ершова О.Б., 20202020Ершова О.Б.Ershova O.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5486

Лечение остеопороза представляет трудную задачу в связи с необходимостью длительного приема лекарственных препаратов и обеспечения максимальной безопасности. Основная цель лечения остеопороза – предотвращение переломов костей. Согласно данным национальных клинических рекомендаций по лечению остеопороза, азотсодержащие бисфосфонаты относятся к препаратам первой линии для профилактики и лечения данного заболевания. Разнообразие в структуре боковых цепей определяет силу, с которой бисфосфонаты связываются с гидроксиапатитом, распределяются и остаются в костной ткани определенное время после того, как лечение было завершено. Они являются препаратами выбора, так как имеют доказанную эффективность в отношении снижения риска переломов и при этом приемлемый профиль безопасности. Бисфосфонаты являются наиболее известными и изученными препаратами, с успехом применяемыми во всех странах для лечения различных форм остеопороза. При использовании пероральных форм бисфосфонатов самым ожидаемым нежелательным явлением являются эзофагиты. Создание новых форм уже известных и доказавших свою эффективность медикаментов, обеспечивающих снижение нежелательных явлений и повышающих приверженность к лечению, представляется крайне важным и перспективным. Из последних достижений в этом плане следует отметить новую форму алендроната – Биносто – шипучую растворимую таблетку, использование которой уменьшает риск раздражающего воздействия на верхние отделы ЖКТ.

Treatment of osteoporosis is a difficult task due to the need for long-term medication and maximum safety. The main goal of osteoporosis treatment is to prevent bone fractures. According to the national clinical guidelines for the treatment of osteoporosis, nitrogen-containing bisphosphonates are among the first-line drugs for the prevention and treatment of this disease. The diversity in the side chain structure determines the strength with which bisphosphonates bind to hydroxyapatite, are distributed, and remain in bone tissue for a certain time after treatment has been completed. They are the drugs of choice as they have proven efficacy in reducing the risk of fractures, and at the same time an acceptable safety profile. Bisphosphonates are the most well-known and studied drugs, successfully used in all countries for the treatment of various forms of osteoporosis. When using oral forms of bisphosphonates, the most expected undesirable phenomenon is esophagitis. The development of new forms of well-known and proven medicines that reduce adverse events and increase adherence to treatment is extremely important and promising. Of the latest achievements in this regard, it should be noted a new form of alendronate-Binosto-effervescent soluble tablet, the use of which reduces the risk of irritating effects on the upper gastrointestinal tract.

остеопорозалендронатнежелательные явленияновая форма алендронатаБиностоosteoporosisalendronateadverse eventsnew form of the alendronateBinostoReferencesFleisch H., Russell R.G.G., Straumann F. Effect of pyrophosphonate on bydroxyapatite and its implications in calcium homeostasis. Nature. 1966;12:901-903. doi: 10.1038/212901a0.Fleisch H., Russell R.G.G., Straumann F. Effect of pyrophosphonate on bydroxyapatite and its implications in calcium homeostasis. Nature. 1966;12:901-903. doi: 10.1038/212901a0.Russell R.G. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19. doi: 10.1016/j.bone.2011.04.022.Russell R.G. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19. doi: 10.1016/j.bone.2011.04.022.Pols H.A., Felsenberg D., Hanley D.A. et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporos Int. 1999;9:461–468. doi: 10.1007/PL00004171.Pols H.A., Felsenberg D., Hanley D.A. et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporos Int. 1999;9:461–468. doi: 10.1007/PL00004171.Black D.M., Thompson D.E., Bauer D.C. and FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85(11):4118-4124. doi: 10.1210/jcem.85.11.6953.Black D.M., Thompson D.E., Bauer D.C. and FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85(11):4118-4124. doi: 10.1210/jcem.85.11.6953.Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938. doi: 10.1001/jama.296.24.2927. Лесняк О.М., Беневоленская Л.И. (ред.). Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2009. 272 с. Lesnyak O.M., Benevolenskaya L.I. (ed.). Osteoporosis. Diagnosis, prevention and treatment. Clinical guidelines. 2nd ed., revised and updated. М.: GEOTARMedia Publishing Group; 2009. 272 p. (In Russ.)Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938. doi: 10.1001/jama.296.24.2927. Лесняк О.М., Беневоленская Л.И. (ред.). Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2009. 272 с. Lesnyak O.M., Benevolenskaya L.I. (ed.). Osteoporosis. Diagnosis, prevention and treatment. Clinical guidelines. 2nd ed., revised and updated. М.: GEOTARMedia Publishing Group; 2009. 272 p. (In Russ.)Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99. doi: 10.1056/NEJMoa030897.Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99. doi: 10.1056/NEJMoa030897.Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., Coyle D., Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155. doi: 10.1002/14651858.CD001155.pub2.Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., Coyle D., Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155. doi: 10.1002/14651858.CD001155.pub2.Schnitzer T., Bone H.G., Grepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res. 2000;12:1-12. doi: 10.1007/BF03339822.Schnitzer T., Bone H.G., Grepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res. 2000;12:1-12. doi: 10.1007/BF03339822.Rizzoli R., Greenspan S.L., Bone G. III, Schnitzer T.J., Watts N.B., Adami S., et al. Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. J Bone Mineral Research. 2002;(11):1988-1996. doi: 10.1359/jbmr.2002.17.11.1988.Rizzoli R., Greenspan S.L., Bone G. III, Schnitzer T.J., Watts N.B., Adami S., et al. Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. J Bone Mineral Research. 2002;(11):1988-1996. doi: 10.1359/jbmr.2002.17.11.1988.Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., Palmisano J.J. Patient preference for onceweekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, openlabel, crossover study. Clin Ther. 2002;24(11):1871-1886. doi: 10.1016/s0149-2918(02)80085-6.Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., Palmisano J.J. Patient preference for onceweekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, openlabel, crossover study. Clin Ther. 2002;24(11):1871-1886. doi: 10.1016/s0149-2918(02)80085-6.Greenspan S., Field-Munves E., Tonino R., Smith M., Petruschke R., Wang L., Yates J., de Papp A.E., Palmisano J. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double- blind, placebo-controlled study. Mayo Clin Proc. 2002;77(10):1044-1052. doi: 10.4065/77.10.1044.Greenspan S., Field-Munves E., Tonino R., Smith M., Petruschke R., Wang L., Yates J., de Papp A.E., Palmisano J. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double- blind, placebo-controlled study. Mayo Clin Proc. 2002;77(10):1044-1052. doi: 10.4065/77.10.1044.Lanza F., Sahba B., Schwartz H., Winograd S., Torosis J., Quan H., Reyes R., Musliner T., Daifotis A., Leung A. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002;97(1):58-64. doi: 10.1111/j.1572-0241.2002.05446.x.Lanza F., Sahba B., Schwartz H., Winograd S., Torosis J., Quan H., Reyes R., Musliner T., Daifotis A., Leung A. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002;97(1):58-64. doi: 10.1111/j.1572-0241.2002.05446.x.Cryer B., Miller P., Petruschke R.A., Chen E., Geba G.P., Papp A.E. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005;21(5):599-607. doi: 10.1111/j.1365-2036.2005.02378.x.Cryer B., Miller P., Petruschke R.A., Chen E., Geba G.P., Papp A.E. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005;21(5):599-607. doi: 10.1111/j.1365-2036.2005.02378.x.Мазуров В.И., Лесняк О.М., Белова К.Ю., Ершова О.Б., Зоткин Е.Г., Марченкова Л.А., Кочиш А.Ю., Рожинская Л.Я., Скрипникова И.А. Алгоритмы выбора терапии остеопороза при оказании первичной медико-санитарной помощи и организации льготного лекарственного обеспечения отдельных категорий граждан, имеющих право на получение государственной социальной помощи. Системный обзор и резолюция экспертного совета российской ассоциации по остеопорозу. Профилактическая медицина. 2019;(1):57-65. doi: 10.17116/profmed20192201157. Mazurov V.I., Lesnyak O.M., Belova K.Yu., Ershova O.B., Zotkin E.G., Marchenkova L.A., Kochish A.Yu., Rozhinskaya L.Ya., Skripnikova I.A. Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine and Public Health. 2019;22(1):57-65. (In Russ.) doi: 10.17116/profmed20192201157.Мазуров В.И., Лесняк О.М., Белова К.Ю., Ершова О.Б., Зоткин Е.Г., Марченкова Л.А., Кочиш А.Ю., Рожинская Л.Я., Скрипникова И.А. Алгоритмы выбора терапии остеопороза при оказании первичной медико-санитарной помощи и организации льготного лекарственного обеспечения отдельных категорий граждан, имеющих право на получение государственной социальной помощи. Системный обзор и резолюция экспертного совета российской ассоциации по остеопорозу. Профилактическая медицина. 2019;(1):57-65. doi: 10.17116/profmed20192201157. Mazurov V.I., Lesnyak O.M., Belova K.Yu., Ershova O.B., Zotkin E.G., Marchenkova L.A., Kochish A.Yu., Rozhinskaya L.Ya., Skripnikova I.A. Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine and Public Health. 2019;22(1):57-65. (In Russ.) doi: 10.17116/profmed20192201157.Kanis J.A., Reginster J.Y., Kaufman J.M., Ringe J.D., Adachi J.D., Hiligsmann M., Rizzoli R., Cooper C. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23:213-221. doi: 10.1007/s00198-011-1796-6.Kanis J.A., Reginster J.Y., Kaufman J.M., Ringe J.D., Adachi J.D., Hiligsmann M., Rizzoli R., Cooper C. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23:213-221. doi: 10.1007/s00198-011-1796-6.Tosteson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209-216. doi: 10.1016/s0002-9343(03)00362-0.Tosteson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209-216. doi: 10.1016/s0002-9343(03)00362-0.Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Porras A.G. Clinical pharmacology of alendronate sodium. Osteopor Int. 1993;3(suppl.3):513-516. doi: 10.1007/bf01623002.Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Porras A.G. Clinical pharmacology of alendronate sodium. Osteopor Int. 1993;3(suppl.3):513-516. doi: 10.1007/bf01623002.Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75-85. doi: 10.1023/A:1008626026484.Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75-85. doi: 10.1023/A:1008626026484.Invernizzi M., Cisari C., Carda S. The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin Exp Res. 2015;27(2):107-113. doi: 10.1007/s40520-014-0256-5.Invernizzi M., Cisari C., Carda S. The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin Exp Res. 2015;27(2):107-113. doi: 10.1007/s40520-014-0256-5.Chesnut C.H. 3rd, McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., Singer F.R., Stock J.L., Yood R.A., Delmas P.D. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152. doi: 10.1016/s0002-9343(99)80134-x.Chesnut C.H. 3rd, McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., Singer F.R., Stock J.L., Yood R.A., Delmas P.D. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152. doi: 10.1016/s0002-9343(99)80134-x.Peter C.P., Handt L.K., Smith S.M. Esophageal irritation due to alendronate sodium tablets possible mechanisms. Dig Dis Sci. 1998;43(9):1998-2002. doi: 10.1023/a:1018894827961.Peter C.P., Handt L.K., Smith S.M. Esophageal irritation due to alendronate sodium tablets possible mechanisms. Dig Dis Sci. 1998;43(9):1998-2002. doi: 10.1023/a:1018894827961.Abid S., Mumtaz K., Jafri W., Hamid S., Abbas Z., Shah H.A., Khan A.H. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005;37(8):740-744. doi: 10.1055/s-2005-870129.Abid S., Mumtaz K., Jafri W., Hamid S., Abbas Z., Shah H.A., Khan A.H. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005;37(8):740-744. doi: 10.1055/s-2005-870129.Perkinks A.C., Blackshaw E., Hay P.D. et al. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a singlecenter single-blind, six-period crossover study in healthy female subjects. Clin Ther. 2008;30(5):834-844. doi: 10.1016/j.clinthera.2008.04.018.Perkinks A.C., Blackshaw E., Hay P.D. et al. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a singlecenter single-blind, six-period crossover study in healthy female subjects. Clin Ther. 2008;30(5):834-844. doi: 10.1016/j.clinthera.2008.04.018.Takeuchi K, Kato S, Amagase K. Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate-prophylactic effects of rebamipide. Curr Pharm Des 2011; 17(16):1602-1611. doi: 10.2174/138161211796196927.Takeuchi K, Kato S, Amagase K. Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate-prophylactic effects of rebamipide. Curr Pharm Des 2011; 17(16):1602-1611. doi: 10.2174/138161211796196927.Gomez Acotto C., Antonelli C., Flynn D., McDaid D., Roldan E.J. Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition. Calcif Tissue Int. 2012;91(5):325-334. doi: 10.1007/s00223-012-9639-9.Gomez Acotto C., Antonelli C., Flynn D., McDaid D., Roldan E.J. Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition. Calcif Tissue Int. 2012;91(5):325-334. doi: 10.1007/s00223-012-9639-9.Hodges L.A., Connolly S.M., Winter J., Schmidt T., Stevens H.N.E., Hayward M., Wilson C.G. Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm. 2012;432:57-62. doi: 10.1016/j.ijpharm.2012.04.073.Hodges L.A., Connolly S.M., Winter J., Schmidt T., Stevens H.N.E., Hayward M., Wilson C.G. Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm. 2012;432:57-62. doi: 10.1016/j.ijpharm.2012.04.073.

The authors declare that there are no conflicts of interest present.